Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
39.39
-0.15 (-0.38%)
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with neurological disorders
The company is dedicated to addressing unmet medical needs in this space, particularly in the areas of rare and complex conditions. By leveraging proprietary research and development capabilities, Harmony Biosciences aims to bring forth therapies that improve the quality of life for patients, while also advancing scientific understanding of neurological diseases. Their portfolio includes products targeting specific disorders, reflecting a commitment to enhancing patient outcomes through personalized and effective treatments.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET.
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders.
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026.
